$RDHL News

RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results

RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus Disease

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY

RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.

RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.

Market-Moving News for January 5th

RedHill Expands RHB-102 Clinical Development Addressing GLP-1 Therapy-Related GI Side Effects And Broader GI Indications

Redhill Biopharma Granted U.S. Patent #12,502,381 Titled "SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION"

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma Shared In Vivo Results, Indicating That Opaganib Combined With Venetoclax Reduces Chronic Lymphocytic Leukemia Cells By Half Compared To Controls

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Biopharma Regains Nasdaq Compliance

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Wins ~$10.5M Judgment Against Kukbo; RedHill Has Secured A Korean Court Attachment Grant Against Kukbo Aimed At Preventing Kukbo From Disposing Of Assets Prior To Judgment Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification